Skip to main content

Table 1 Information about the study subjects

From: ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain

Diagnosis

Gender

Age

Braak stage

pm delay (min)

CSF pH

Brain weight (g)

control

F

69

1

375

6.59

1264

control

F

72

1

405

6.52

1296

control

M

79

1

320

6.72

1322

control

M

83

1

275

6.49

1422

control

F

88

2

340

n.d.

1152

Control mean

3F/2 M

78.2

1.2

343

6.58

1291

AD

F

84

4

230

6.64

1196

AD

F

85

4

220

6.59

1065

AD

F

93

4

335

6.65

1194

AD

F

84

4

230

6.64

1196

AD

F

87

4

240

6.91

955

AD

F

101

4

265

6.93

1016

AD

M

91

4

250

n.d.

1160

AD/LBV

F

81

4

193

6.54

1096

AD/LBV

F

76

4

295

6.78

1180

AD

M

67

5

260

6.62

1094

AD

F

77

5

252

6.43

1151

AD

F

77

5

215

6.67

1235

AD

M

86

5

335

6.39

1315

AD

M

95

5

185

6.4

1203

AD

M

70

5

525

6.25

1220

AD/LBV

M

80

5

1670

6.19

1170

AD/LBV

F

69

5

295

6.59

1039

AD/LBV

F

84

5

365

6.1

1116

AD/LBV

F

87

5

260

6.17

1022

AD/LBV

M

84

5

275

6.54

1373

AD

M

58

6

385

6.42

1273

AD

F

87

6

300

6.66

852

AD

F

87

6

250

6.9

1047

AD

F

77

6

285

6.74

1116

AD

F

91

6

275

6.55

949

AD

F

66

6

215

6.42

1105

AD/LBV

M

54

6

610

6.51

1334

AD/LBV

F

69

6

295

6.41

1003

AD mean

19 F/9 M

80.3

5

340

6.54

1131

  1. There were no statistically significant differences in age, cerebrospinal fluid (CSF) pH or pm delay between AD patients (Braak stages 4, 5 and 6) and controls (Braak stage 1 and 2). Brain weight was significantly lower in the AD patients, compared to controls (p = 0.01, unpaired t-test).